#USA #Boston #Volta Labs #Callisto #AGBT 2026

Volta Labs Drives Innovation at AGBT 2026

In a landmark announcement today, Volta Labs showcased an impressive array of product launches, strategic collaborations, and client presentations that set the stage for significant advancements in genomic sequencing at the AGBT 2026 conference. The initiative marks a pivotal moment in the evolution of automated genomics, positioning Volta Labs at the forefront of this ever-changing field.

Significant Product Developments

One of the core highlights of the event was the introduction of Roche AXELIOS 1, set to integrate seamlessly with Volta's advanced Callisto™ platform. This integration is expected to shift the paradigm of automating genomic workflows from manual execution to immediate, streamlined processes. Callisto™ already boasts integrated DNA extraction workflows, emphasizing Volta's commitment to providing high-quality automated library preparation for advanced sequencing systems.

The Partnership with Roche and Watchmaker Genomics

In collaboration with Watchmaker Genomics™, Volta Labs introduced the new Callisto™ kit, designed for comprehensive DNA library preparation. This innovative solution boasts the ability to perform whole genome sequencing without PCR, thereby minimizing manual intervention while ensuring high reproducibility and outstanding data quality. The rollout signifies a major leap toward making the highest quality genome sequencing accessible without complicating laboratory workflows.

The highlight of Volta's presentation was the practical application of Callisto™ during the Hartwig Medical Foundation's showcase. The foundation demonstrated its exploration of circulating tumor DNA (ctDNA) as a key component in patient monitoring and therapy selection. With the fully automated cfDNA workflow powered by Callisto, Hartwig underlined its effectiveness in generating clinical-grade genomic data from complex samples, contributing enormous value to the oncology field.

Real-World Data and Client Validation

At the event, prestigious institutions like UMC Utrecht and the Hartwig Medical Foundation shared compelling data from high-performance settings where they have successfully employed the Callisto platform. Both organizations have been utilizing Callisto for nearly a year, showcasing significant enhancements in operational efficiency, consistency, and reproducibility.

As Bert Van der Zwaag, a laboratory geneticist at UMC Utrecht, explained, "Since our partnership with Volta Labs, we have effectively integrated Callisto into our diagnostic environment, processing thousands of patient samples and witnessing a demand that exceeds our capabilities. This underscores Callisto's reliability and utility, prompting us to expand our use and standardize workflows across our laboratory."

Transition to Application-Based Genomics

Volta Labs is not just about reacting to advancements but looks ahead by showcasing an expanding collection of pre-designed applications expected to be rolled out by 2026. This move aims to reshape the landscape of genomics toward a model that favors validated workflows rather than the costly and repetitive development of new methods.

Udayan Umapathi, CEO of Volta Labs, emphasized, "Innovation in sequencing does not need every lab to reinvent their workflows. We are propelling the industry towards a truly automated genomic environment where instant sequencing becomes the norm, not the exception."

Conclusion

The advances presented by Volta Labs at AGBT 2026 showcase a promising future for genomic automation. By harnessing partnerships and innovations, they aim to facilitate seamless genomic workflows and ultimately enhance the impact of genomics on patient care and research. The interplay of technology and strategic collaboration is paving the way for a transformation that could redefine the field of genomic science.

For more information about Volta Labs and their revolutionary offerings, visit their official website or follow their updates as they lead the charge in shaping the genomic landscape.

About Volta Labs

Based in Boston, Massachusetts, Volta Labs is pioneering a new future in sample preparation for sequencing by blending digital fluidics, modular workflows, and complete automation into a single unified platform. Their flagship product, Callisto™, enables high-quality and reproducible NGS library preparation optimized for various genomic applications.